# Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus

> **NCT03695029** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Hepatitis B Virus Infection

## Interventions

- **DRUG:** Tenofovir Alafenamide

## Key facts

- **NCT ID:** NCT03695029
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12-29
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03695029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03695029, "Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03695029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*